NMN for Energy and Fatigue: What the Clinical Evidence Shows

NMN for Energy and Fatigue is one of the most searched topics in the longevity supplement space, and for good reason: chronic low energy is one of the top complaints that drives people toward NAD+ precursors. But before you spend money on any supplement, you need to know what the actual human trials say—and what they don't. This article breaks down the clinical evidence on NMN and energy metabolism, muscle function, and subjective fatigue, without the hype.

The Evidence Base

As of 2026, the human clinical literature on NMN consists of a small but growing number of randomized controlled trials (RCTs), mostly in Japanese and Chinese populations, with sample sizes ranging from 10 to 48 participants. No large-scale, multi-center RCTs exist yet. That context matters: the effects we discuss are real, but they come from early-phase studies that need replication.

The most relevant trials for energy and fatigue come from four key studies. Yoshino et al. (2021) conducted a randomized, placebo-controlled, crossover trial in 25 postmenopausal women with prediabetes, giving 250 mg NMN daily for 10 weeks. Igarashi et al. (2022) ran a 12-week RCT in 42 healthy older men (65+ years) using 250 mg/day. Irie et al. (2020) performed an open-label, non-randomized study in 10 healthy Japanese men with single doses ranging from 100 to 500 mg. Liao et al. (2021) studied 48 amateur runners in a double-blind RCT using 300–1200 mg/day over 6 weeks to measure aerobic capacity.

What these studies collectively show: NMN reliably raises blood NAD+ metabolites, and some—but not all—energy-related biomarkers improve. The effects are most pronounced in older adults and those with metabolic dysfunction, not necessarily in young, healthy people.

Study	Population	Dose & Duration	Design	Key Energy-Related Outcome	Evidence Quality
Yoshino et al. (2021)	25 prediabetic women, 55–75 yr	250 mg/day, 10 weeks	RCT, crossover, placebo-controlled	Improved muscle insulin sensitivity; no direct fatigue measure	Moderate
Igarashi et al. (2022)	42 healthy older men, 65+ yr	250 mg/day, 12 weeks	RCT, double-blind, placebo-controlled	Improved gait speed, grip strength, muscle oxygen utilization	Moderate
Irie et al. (2020)	10 healthy men, 20–60 yr	100–500 mg, single dose	Open-label, non-randomized	Well-tolerated; NAD+ metabolites elevated; no functional measures	Limited data
Liao et al. (2021)	48 amateur runners, 27–50 yr	300–1200 mg/day, 6 weeks	RCT, double-blind, placebo-controlled	Improved aerobic capacity (VO2 metrics) at higher doses	Moderate
Niu et al. (2023)	8 pre-aging adults, 45–60 yr	300 mg/day, 8 weeks	Single-arm, open-label	Serum metabolic shifts; no direct energy or fatigue endpoints	Limited data

The Mechanism

NMN, or nicotinamide mononucleotide, is a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme that exists in every cell of your body. NAD+ is not a fuel itself—it is a carrier molecule that shuttles electrons during metabolic reactions. Without adequate NAD+, your mitochondria cannot perform oxidative phosphorylation efficiently, which is how cells generate the majority of their ATP.

Gomes et al. (2013) demonstrated in mouse models that declining NAD+ with age disrupts the communication between the nucleus and mitochondria, creating what the authors termed a "pseudohypoxic state." Even when oxygen is present, cells behave as if they are starved of it, downregulating genes involved in oxidative metabolism. This is a foundational paper, but it is animal data. Whether the same nuclear-mitochondrial disruption occurs in humans at a clinically relevant scale is still being investigated.

NMN is one of several ways to raise NAD+ levels. It enters cells either directly (via specific transporters discovered in recent years) or converts to NR (nicotinamide riboside) first, then to NAD+. The key point: oral NMN is bioavailable in humans. Irie et al. (2020) showed dose-dependent increases in blood NMN and NAD+ metabolites within hours of ingestion. It gets into the bloodstream. What happens after that—how much reaches muscle tissue, brain tissue, or mitochondria—is less precisely quantified.

What the Trials Actually Measured

Here is where nuance becomes critical. None of the major human NMN trials used a validated fatigue questionnaire like the Chalder Fatigue Scale or PROMIS as a primary endpoint. If you are taking NMN hoping for a subjective energy boost, the direct evidence is weaker than you might expect from marketing copy.

Yoshino et al. (2021) measured muscle insulin sensitivity via hyperinsulinemic-euglycemic clamp—the gold standard for glucose disposal. Participants on NMN showed improved insulin-stimulated glucose disposal in skeletal muscle. Better insulin sensitivity means muscle cells can access glucose more efficiently, which is mechanistically linked to sustained energy. But the study did not measure perceived energy, daily functioning, or fatigue.

Igarashi et al. (2022) came closer to functional outcomes. In healthy older men, 12 weeks of 250 mg NMN improved gait speed, left-hand grip strength, and muscle oxygen consumption during exercise. These are objective proxies for physical vitality. The authors also noted improvements in auditory function, suggesting systemic effects beyond muscle. Again, no fatigue scale was used, but the functional gains in older adults are the most clinically relevant energy-related data we have.

Liao et al. (2021) is the only study to examine exercise performance directly. Amateur runners taking 600–1200 mg/day showed improved VO2 max, percentage of ventilatory threshold, and exercise economy compared to placebo. The 300 mg dose showed no significant benefit. This dose-response pattern is important: more was not infinitely better, but the lower end of the studied range was insufficient for this population and endpoint.

Niu et al. (2023) used metabolomics to show that 8 weeks of 300 mg NMN altered serum metabolite profiles in pre-aging adults, shifting pathways related to energy metabolism. This is exploratory data—interesting, but not proof of improved energy or reduced fatigue.

What the Evidence Doesn't Show

Let's be explicit about the gaps. First, there are no published RCTs of NMN in people with diagnosed chronic fatigue syndrome (ME/CFS), fibromyalgia, or idiopathic fatigue. The fatigue-related claims you see online are extrapolated from metabolic studies in healthy or prediabetic populations.

Second, no head-to-head trial compares NMN to NR (nicotinamide riboside), NAD+ IV therapy, or simple lifestyle interventions like sleep improvement or resistance training. We do not know if NMN is superior to cheaper or non-supplement alternatives for energy.

Third, the long-term safety data beyond 12–16 weeks is sparse. The short-term studies show good tolerability—no serious adverse events at doses up to 1200 mg/day—but that is not the same as knowing what happens after two years of daily use.

Fourth, the "energy" improvements seen in older adults may reflect reversal of age-related NAD+ decline rather than a stimulant effect. A 30-year-old with normal NAD+ levels may not experience the same functional gains as a 70-year-old with depleted levels. This is not a caffeine-like boost. It is metabolic restoration, and the magnitude depends on your baseline.

Who Benefits Most

Based on the current evidence, the populations with the strongest signal for NMN-related energy and functional improvements are:

• Older adults (60+) with declining physical performance. Igarashi et al. (2022) showed objective gains in muscle function in this group at 250 mg/day.
• People with prediabetes or insulin resistance. Yoshino et al. (2021) demonstrated improved muscle insulin sensitivity, which supports better glucose utilization and sustained energy.
• Recreational athletes seeking aerobic gains. Liao et al. (2021) showed dose-dependent improvements in VO2-related metrics at 600+ mg/day.
• Individuals in the "pre-aging" phase (45–60) with subclinical metabolic shifts. Niu et al. (2023) suggests metabolic flexibility may improve, though functional data is lacking.

Young, healthy adults with no metabolic dysfunction have the weakest evidence base for noticeable energy changes. If you are 25, sleeping well, and exercising regularly, the trials do not suggest NMN will give you a perceptible boost.

For those who fall into the stronger-evidence categories, product form and dose matter. A once-daily capsule delivering Bio:sudo NMN 1000mg provides a dose at the upper end of the studied range, which aligns with the Liao et al. (2021) protocol where 600–1200 mg showed aerobic benefits. However, Yoshino and Igarashi saw meaningful effects at just 250 mg, so more is not necessarily required for metabolic or muscle function endpoints.

Practical Takeaways

• NMN raises NAD+ reliably in humans, but improved energy and reduced fatigue are inferred from metabolic and functional endpoints, not direct fatigue scales.
• The strongest evidence is in older adults and those with metabolic dysfunction, not young, healthy populations.
• Dose matters by goal: 250 mg/day showed muscle and metabolic benefits in two RCTs; 600–1200 mg/day showed aerobic capacity gains in runners.
• Expect metabolic restoration, not stimulation. NMN is not a stimulant. Any energy improvement likely comes from better mitochondrial efficiency and insulin sensitivity, not acute activation.
• Safety at studied doses is good, but long-term data is limited. Most trials ran 6–12 weeks.
• Lifestyle factors dominate. Sleep, resistance training, and protein intake will likely improve energy more reliably than any supplement if those are currently suboptimal.

For a deeper look at the full spectrum of NMN research—including claims that still lack human support—see our breakdown of NMN benefits with actual human evidence. If you want to understand why NAD+ decline matters in the first place, read Cellular Vitality 101. And for help navigating dosing decisions, our NMN dosage guide breaks down why lower doses may suffice for some goals while higher doses target performance endpoints.

Bottom Line

The clinical evidence for NMN improving energy and fatigue is preliminary but promising, particularly for older adults and people with metabolic dysfunction. The mechanism—restoring NAD+ to support mitochondrial function and insulin sensitivity—is biologically plausible and supported by human data. However, no trial has directly measured subjective fatigue reduction, and the long-term safety profile remains incompletely characterized. NMN is not a miracle energy solution, but for the right population, it is one of the more evidence-grounded options in the NAD+ precursor category.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---